{"entity":{"id":"interlace","kind":"trial","name":"INTERLACE","aka":[],"tldr":"Six weeks of cheap, generic chemotherapy before standard chemoradiation cut deaths by 40%, an advance usable anywhere in the world.","summary":"INTERLACE, trial NCT01566240 sponsored by the UCL Cancer Trials Centre and Cancer Research UK and published in the Lancet in 2024, showed that six weeks of cheap, generic carboplatin and paclitaxel before standard chemoradiation for locally advanced cervical cancer cut deaths by forty percent, an advance usable anywhere in the world. It randomised 500 patients across 32 centres in five countries including India and Mexico and met its primary progression-free and overall survival endpoints at five years. Earlier neoadjuvant trials before surgery were negative, so this short induction before radiation is a distinct strategy not yet reproduced, and it is the pragmatic choice where pembrolizumab is unaffordable.","status":"positive","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT01566240","url":"https://clinicaltrials.gov/study/NCT01566240"},{"label":"Lancet 2024","url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01438-7/fulltext"}],"tags":[],"related":[],"cancers":["cervical","locally-advanced-cervical-cancer"],"sections":[],"technologies":["imrt-igrt","brachytherapy","cytotoxic-chemotherapy"],"targets":[],"drugs":["carboplatin","paclitaxel","cisplatin"],"companies":[],"institutions":["cruk"],"pathways":[],"terms":[],"trials":[],"people":["mary-mccormack"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01566240","phase":"3","setting":"Locally advanced cervical cancer: 6 weeks of induction carboplatin-paclitaxel before chemoradiation vs chemoradiation alone","sponsor":"UCL Cancer Trials Centre / CRUK","result":"5-year OS 80% vs 72% (HR 0.60); PFS HR 0.65.","started":"2012-11-08","startedType":"actual","yearReported":2023,"enrolled":500,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free survival at 5 years","primary":true,"unit":"%","arms":[{"name":"Induction chemo + CRT","n":250,"value":72},{"name":"CRT alone","n":250,"value":64}],"hr":0.65,"ci":[0.46,0.91],"source":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01438-7/fulltext"},{"endpoint":"Overall survival at 5 years","primary":true,"unit":"%","arms":[{"name":"Induction chemo + CRT","value":80},{"name":"CRT alone","value":72}],"hr":0.6,"ci":[0.4,0.91],"source":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01438-7/fulltext"}],"replication":"Earlier neoadjuvant chemotherapy trials before surgery (EORTC 55994) were negative; INTERLACE's short weekly induction before radiation is a distinct strategy not yet reproduced."},"route":"/trials/interlace/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"locally-advanced-cervical-cancer","kind":"cancer","name":"Locally advanced cervical cancer","route":"/cancers/locally-advanced-cervical-cancer/"}],"technology":[{"id":"brachytherapy","kind":"technology","name":"Brachytherapy","route":"/technologies/brachytherapy/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"institution":[{"id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/"}],"person":[{"id":"mary-mccormack","kind":"person","name":"Mary McCormack","route":"/people/mary-mccormack/"}],"pairing":[{"id":"induction-chemo-then-crt","kind":"pairing","name":"Induction chemotherapy → chemoradiation (locally advanced cervical cancer)","route":"/pairings/induction-chemo-then-crt/"}],"paper":[{"id":"paper-interlace-lancet-2024","kind":"paper","name":"INTERLACE: induction chemotherapy before chemoradiotherapy for locally advanced cervical cancer","route":"/key-papers/paper-interlace-lancet-2024/"}],"term":[{"id":"randomised-trial","kind":"term","name":"Randomised trial","route":"/terms/randomised-trial/"}],"roadmap":[{"id":"chemotherapy-roadmap","kind":"roadmap","name":"Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs","route":"/roadmaps/chemotherapy-roadmap/"},{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/"},{"id":"radiation-roadmap","kind":"roadmap","name":"Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH","route":"/roadmaps/radiation-roadmap/"}]}}